High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

Options for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after brentuximab vedotin (Bv) and autologous stem cell transplantation (ASCT) are limited. Immune checkpoint inhibitors (ICI) are active in this population but rarely induce complete response (CR). Ten patients...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Hematol Oncol
Egile Nagusiak: Falchi, Lorenzo, Sawas, Ahmed, Deng, Changchun, Amengual, Jennifer E., Colbourn, Donald S., Lichtenstein, Emily A., Khan, Karen A., Schwartz, Lawrence H., O’Connor, Owen A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2016
Gaiak:
Letter to the Editor
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5129196/
https://ncbi.nlm.nih.gov/pubmed/27899158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0363-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak